Cobicistat: A Review of Its Use as a Pharmacokinetic Enhancer of Atazanavir and Darunavir in Patients with HIV-1 Infection
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cobicistat: A Review of Its Use as a Pharmacokinetic Enhancer of Atazanavir and Darunavir in Patients with HIV-1 Infection
Authors
Keywords
Ritonavir, Atazanavir, Tenofovir Disoproxil Fumarate, Darunavir, Cobicistat
Journal
DRUGS
Volume 74, Issue 2, Pages 195-206
Publisher
Springer Nature
Online
2013-12-16
DOI
10.1007/s40265-013-0160-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Evaluation of the Effect of Cobicistat on theIn VitroRenal Transport and Cytotoxicity Potential of Tenofovir
- (2013) Kirsten M. Stray et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen (Stribild®): A Review of Its Use in the Management of HIV-1 Infection in Adults
- (2013) Caroline M. Perry DRUGS
- The Pharmacokinetic and Pharmacodynamic Interactions Between Buprenorphine/Naloxone and Elvitegravir/Cobicistat in Subjects Receiving Chronic Buprenorphine/Naloxone Treatment
- (2013) Robert Douglas Bruce et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Boosting HIV Treatment Options: Good News, New Challenges
- (2013) Pedro Cahn et al. JOURNAL OF INFECTIOUS DISEASES
- Cobicistat Versus Ritonavir as a Pharmacoenhancer of Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-Naive HIV Type 1–Infected Patients: Week 48 Results
- (2013) Joel E. Gallant et al. JOURNAL OF INFECTIOUS DISEASES
- Cobicistat: A New Boost for the Treatment of Human Immunodeficiency Virus Infection
- (2013) Bhavik M. Shah et al. PHARMACOTHERAPY
- Cobicistat Boosts the Intestinal Absorption of Transport Substrates, Including HIV Protease Inhibitors and GS-7340,In Vitro
- (2012) Eve-Irene Lepist et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Phase 2 study of cobicistat versus ritonavir each with once-daily atazanavir and fixed-dose emtricitabine/tenofovir df in the initial treatment of HIV infection
- (2011) Richard Elion et al. AIDS
- Scientific Considerations for Pharmacoenhancers in Antiretroviral Therapy
- (2011) Vikram Arya et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Drug resistance in HIV-1
- (2011) Daniel R Kuritzkes Current Opinion in Virology
- Biological Profiling of GS-9350, a Novel Pharmacoenhancer that Lacks Anti-HIV Activity and Exhibits Low Potential for Metabolic Adverse Effects In Vitro
- (2010) Christian Callebaut et al. ANTIVIRAL RESEARCH
- Drug-drug interactions in the treatment of HIV infection: focus on pharmacokinetic enhancement through CYP3A inhibition
- (2010) F. Josephson JOURNAL OF INTERNAL MEDICINE
- Cobicistat (GS-9350): A Potent and Selective Inhibitor of Human CYP3A as a Novel Pharmacoenhancer
- (2010) Lianhong Xu et al. ACS Medicinal Chemistry Letters
- Pharmacokinetics and Pharmacodynamics of GS-9350: A Novel Pharmacokinetic Enhancer Without Anti-HIV Activity
- (2009) A A Mathias et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Atazanavir
- (2009) Katherine F. Croom et al. DRUGS
- Efficacy and Safety of Once-Daily Regimens in the Treatment of HIV Infection
- (2008) Jean-Michel Molina DRUGS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation